NICE gives initial no for Novartis's Glivec for post surgery GIST
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, is not minded to recommend Novartis's Glivec (imatinib) as an adjuvant treatment for gastrointestinal stromal tumours (GIST) for use on the NHS, it says in preliminary draft guidance published yesterday.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.